BioAtla (NASDAQ:BCAB) Raised to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of BioAtla (NASDAQ:BCAB) to a sell rating in a report published on Saturday morning.

A number of other brokerages have also weighed in on BCAB. JMP Securities reissued a “market perform” rating on shares of BioAtla in a report on Wednesday, August 13th. Citizens Jmp lowered shares of BioAtla from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 13th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, BioAtla presently has a consensus rating of “Hold” and a consensus price target of $5.00.

BioAtla Stock Up 13.9%

Shares of BCAB opened at $0.61 on Friday. The stock has a market cap of $35.89 million, a price-to-earnings ratio of -0.56 and a beta of 0.92. BioAtla has a 12 month low of $0.24 and a 12 month high of $2.53. The company has a 50-day moving average price of $0.39 and a two-hundred day moving average price of $0.39.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Thursday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). Equities research analysts expect that BioAtla will post -1.46 EPS for the current fiscal year.

Hedge Funds Weigh In On BioAtla

Several institutional investors and hedge funds have recently made changes to their positions in the company. Acorn Capital Advisors LLC grew its holdings in shares of BioAtla by 19.9% in the 2nd quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock valued at $1,915,000 after buying an additional 803,065 shares during the period. Acadian Asset Management LLC grew its holdings in shares of BioAtla by 968.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock valued at $585,000 after buying an additional 1,531,994 shares during the period. Woodline Partners LP acquired a new position in shares of BioAtla in the 1st quarter valued at $26,000. Two Sigma Investments LP grew its holdings in shares of BioAtla by 84.0% in the 4th quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after buying an additional 61,725 shares during the period. Finally, Tang Capital Management LLC grew its holdings in shares of BioAtla by 57.2% in the 4th quarter. Tang Capital Management LLC now owns 1,374,076 shares of the company’s stock valued at $812,000 after buying an additional 500,000 shares during the period. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.